Motley Fool  Apr 7  Comment 
Both of these pharmaceutical giants are trading at cheap valuations and offer big dividends, due to troubles that are mostly behind them.
FiercePharma  Apr 4  Comment 
After Eli Lilly’s Cyramza flopped a phase 3 liver cancer trial in 2014, the company went back to the drawing board to design a trial for a specific subpopulation. Nearly four years later, it’s back with a win.
MarketWatch  Apr 4  Comment 
Eli Lilly & Co. announced Wednesday a collaboration agreement with Sigilon Therapeutics to develop cell therapies for the treatment of type 1 diabetes. Under terms of the agreement, Lilly will pay Siligon $63 million upfront and make an equity...
Motley Fool  Apr 3  Comment 
These two pharma companies are in very different stages of their life cycle, but which is more deserving of capital today?
FierceBiotech  Apr 3  Comment 
The hot NASH arena has a new player, Terns Pharmaceuticals, and it has already got three candidates from Eli Lilly, a $30 million series A backed by Lilly Asia Ventures, and a strategy to go after approval in China first.
FiercePharma  Mar 30  Comment 
Jockeying for market share, Eli Lilly offered more than half off its U.S. list prices in the form of rebates and discounts last year. That 51% average cut stemmed from 9.7% list-price hikes that sank to 6% after wheeling and dealing with payers.
FierceBiotech  Mar 30  Comment 
Eli Lilly is doubling down on novel mechanisms of action to steer clear of the “pile-on effect” seen in PD-1/PD-L1 and other hot targets. The Big Pharma wants to hightail novel approaches into the clinic and up to proof of concept before its...
Motley Fool  Mar 26  Comment 
Biohaven announced a "successful achievement" that failed to impress investors.
GenEng News  Mar 21  Comment 
Scientists in the U.S. have demonstrated that long-term therapy with the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene helps to slow disease progression in a mouse model of one of the most common forms of muscular...

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki